Noninvasive SERS Immunosensing Revolutionizes Melanoma Monitoring via Integrated Microneedle Sampling and Satellite-Structured Nanozymes

July 12, 2026

Analytical Chemistry – ACS Publications USA

Overview

This research reports a noninvasive SERS immunosensing platform for melanoma monitoring, integrating a wearable microneedle (MN) patch with satellite-structured CoFe2O4–Au@Pt nanoparticles possessing both highly efficient mimetic enzyme and SERS activities. The MN patch facilitates sampling of dermal interstitial fluid and immunocapture of tyrosinase, which is then quantified using SERS immunoassay. This technology aims to reduce patient burden and enable earlier, more frequent monitoring.

In Depth

Key Findings

An innovative Surface-Enhanced Raman Scattering (SERS) immunosensing platform has been developed for noninvasive melanoma monitoring, integrating a wearable microneedle (MN) patch with satellite-structured CoFe2O4–Au@Pt nanoparticles. These nanoparticles uniquely combine highly efficient mimetic enzyme (nanozyme) activity with excellent SERS activity, dramatically enhancing detection sensitivity. The MN patch noninvasively samples dermal interstitial fluid and simultaneously immunocaptures tyrosinase, a key melanoma biomarker, which is then quantified with high precision using the SERS immunoassay. This technology offers a patient-friendly and effective monitoring alternative to conventional invasive biopsies and blood tests.

Technical/Clinical Details

The developed SERS immunosensing platform consists of two main components. First, a wearable MN patch features microneedles that painlessly penetrate the outermost skin layer to collect interstitial fluid. Concurrently, these microneedles are functionalized with specific antibodies to capture the target biomarker, tyrosinase. Second, the detection relies on ‘satellite-structured CoFe2O4–Au@Pt nanoparticles.’ This hybrid structure features a magnetic core (CoFe2O4) with gold (Au) and platinum (Pt) nanoparticles attached like satellites. Pt provides nanozyme activity, while the CoFe2O4-Au composite offers plasmonic properties that enhance the SERS signal. The captured tyrosinase binds to secondary antibodies labeled with these nanoparticles, leading to SERS detection. The nanozyme activity further amplifies the Raman signal, enabling the detection of tyrosinase at ultra-low concentrations. This combination of noninvasive sampling and highly sensitive detection opens the possibility for patients to regularly monitor melanoma progression and treatment response from home.

Background and Industry Context

Melanoma is the most aggressive form of skin cancer, and early diagnosis and continuous monitoring significantly impact patient prognosis. However, current monitoring methods often involve invasive procedures (like biopsies) or require regular hospital visits and blood draws, imposing physical and psychological burdens on patients and making frequent monitoring challenging. Tyrosinase, an enzyme involved in melanin synthesis, is known to be secreted by melanoma cells, making its concentration in blood and tissue a promising biomarker for melanoma progression and recurrence. This research’s noninvasive SERS immunosensing offers a novel approach to detect tyrosinase painlessly and with high sensitivity, addressing a significant unmet need in melanoma management.

Strategic Significance & Outlook

This innovative SERS immunosensing platform has the potential to fundamentally change how melanoma patients are monitored. In the future, the MN patch is expected to be further developed to possess multiplex sensing capabilities, allowing for the simultaneous detection of multiple melanoma-related biomarkers. This would enable a more comprehensive profiling of the disease and a more precise evaluation of treatment responses. Furthermore, integration with smartphone applications could form the basis of a telemedicine system, where patients conduct self-monitoring at home and share data with healthcare providers in real-time. Clinical application of this technology is strongly anticipated to improve patients’ quality of life, accelerate early detection and therapeutic intervention for melanoma, and ultimately contribute to improved patient survival rates. Further clinical validation and regulatory approval will be key to its widespread adoption.

Source: https://pubs.acs.org/doi/10.1021/acs.analchem.6c01543

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.